Product Description: JNJ-70218902 is a bispecific antibody that binds to human TMEFF2 on cancer cells and to human CD3 on T cells. JNJ-70218902 induces an exposure-dependent proinflammatory response and targeted tumor cell lysis, and promotes T cell-mediated tumor cell killing (EC50: 1.4 nM). JNJ-70218902 has a promising potential for prostate cancer research. The recommended isotype control is human IgG4 kappa, isotype control (HY-P99003)[1].
Applications: Cancer-programmed cell death
Formula: N/A
References: [1]Basu S et al. Abstract LB087: Characterization of JNJ-70218902, a TMEFF2 x CD3 bispecific antibody, in prostate cancer models Cancer Research 82.12_Supplement (2022): LB087-LB087. /[2]Lowenstein C, et al. 1360 Pharmacodynamics of JNJ-70218902, a TMEFF2× CD3 bispecific antibody, in cynomolgus monkey. (2022).
Molecular Weight: N/A
Research Area: Cancer
Target: CD3;Transmembrane Glycoprotein
English
Deutsch
